Tübingen, Germany, 23.4.2021 – CORAT Therapeutics initiated a Phase Ib/II clinical trial evaluating the safety, tolerability, and efficacy of COR-101 in a total of 45 patients at five sites in Germany
CORAT Therapeutics GmbH announced the start of a clinical trial with COR-101 for treatment of COVID-19 in hospitalized patients. The novel therapeutic antibody may complement currently approved antibody drugs, which are not indicated for moderate to severe COVID-19 cases due to side effects during advanced stages of the disease. Yesterday, the first patient was treated at the University Hospital of Tuebingen under the direction of Prof. Dr. Helmut Salih, Medical Director of the Clinical Cooperation Unit (KKE) Translational Immunology and national coordinating investigator of the clinical trial.
“The promising antibody drug COR-101 shows that research made in Lower Saxony can provide an important building block on the way out of the pandemic. The clinical test phase that started yesterday gives hope that the Braunschweig project can soon save lives.”
Dr. Bernd Althusmann, Lower Saxony Minister of Economic Affairs
